• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Supernus Pharm (NQ: SUPN )

    26.91 -0.13 (-0.48%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 443,179
    Open 27.08
    Bid (Size) 25.96 (1)
    Ask (Size) 27.89 (1)
    Prev. Close 27.04
    Today's Range 26.86 - 27.58
    52wk Range 21.99 - 35.44
    Shares Outstanding 53,145,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents.
    SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) stands out as a stock that provides good value for the fundamentals it showcases. 
    Via Chartmill
    Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -2.96%
    -2.96%
    1 Month
    -2.18%
    -2.18%
    3 Month
    -17.83%
    -17.83%
    6 Month
    -8.93%
    -8.93%
    1 Year
    -11.45%
    -11.45%

    More News

    Read More
    Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Recap: Supernus Pharmaceuticals Q4 Earnings
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    Supernus Pharmaceuticals: Q3 Earnings Insights
    Via Benzinga
    SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
    Via InvestorPlace
    Supernus Announces First Quarter 2024 Financial Results
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Supernus Provides Regulatory Update for SPN-830
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Biotechnology And Healthcare, A Bit Of A Lull
    Via Talk Markets
    Supernus to Participate in Two Upcoming Investor Conferences
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
    Via InvestorPlace
    Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
    Via Benzinga
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.